Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atorvastatin for prevention of acute GVHD

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

NCT01491958

Acute Myelogenous Leukemia Acute Lymphocytic Leukemia Myelodysplastic Syndrome

COMPLETED PHASE2

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

NCT01525407

Malignant Neoplasm

COMPLETED PHASE2

Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation

NCT01665677

Graft vs Host Disease

COMPLETED PHASE2

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

NCT01527045

Aggressive Non-Hodgkin Lymphoma Blasts Under 5 Percent of Bone Marrow Nucleated Cells Chronic Lymphocytic Leukemia +18 more

COMPLETED PHASE2

Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT

NCT03066466

Acute Myeloid Leukemia Acute Lymphocytic Leukemia Myelodysplastic Syndrome

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase II study of atorvastatin for the prophylaxis of acute GVHD in patients undergoing matched-sibling allogeneic HSCT. This study will explore a two-pronged acute GVHD prophylaxis strategy, consisting of pre-treating consenting sibling donors with atorvastatin before stem cell collection, followed by the addition of atorvastatin to methotrexate/tacrolimus-based GVHD prophylaxis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Graft vs Host Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Recipient - Atorvastatin to prevent GVHD

Atorvastatin calcium (Lipitor) will be administered at dose of 40mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning. Patients will receive atorvastatin until +180 days or development of grade 2 GVHD. This is the experimental arm for outcome measures.

Group Type EXPERIMENTAL

Atorvastatin calcium (Lipitor)

Intervention Type DRUG

40 mg PO daily

Donor - Atorvastatin conditioning for donors

Sibling donors will start taking Atorvastatin calcium (Lipitor) orally at 40mg once daily between 14-28 days before the anticipated first day of apheresis or bone marrow harvest.

Group Type OTHER

Atorvastatin calcium (Lipitor)

Intervention Type DRUG

40 mg PO daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atorvastatin calcium (Lipitor)

40 mg PO daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lipitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

7. No clinical evidence of uncontrolled active bacterial, viral or fungal infection at the time of stem cell mobilization.
8. Donors must have a Karnofsky performance score of ≥60.
9. Donors with history of intolerance or allergic reactions with atorvastatin will not be eligible. Hypersensitivity to any component of atorvastatin.
10. Method of stem-cell collection from the sibling donor will be at the discretion of the treating physician. Although it is anticipated that majority of sibling donors will undergo G-CSF induced stem cell mobilization; however donors undergoing bone marrow harvest or stem cell mobilization with experimental agents (e.g. plerixafor) will remain eligible for the study.

PATIENT ELIGIBILITY CRITERIA:

1. Patients with a history of a hematological malignancy or bone marrow failure syndrome suitable for matched sibling allogeneic stem cell transplantation in the opinion of treating transplant physician.
2. Patients aged 18-75 years of age are eligible. Patients with age \> 18 and ≤ 50 years will be eligible for myeloablative conditioning (MAC), while patients \> 50 years of age, or those with previous history of autologous transplantation, high hematopoietic cell transplant comorbidity index (HCT-CI) score (\>2), and baseline diagnosis of hodgkin's lymphoma, chronic lymphocytic leukemia and follicular lymphoma will be suitable for reduced intensity conditioning (RIC) transplantation (however intensity of conditioning regimen will remain at the discretion of treating physician).
3. All patients must have at least one suitable HLA-matched sibling donor according to transplant center's guidelines (for selection of appropriate sibling donor).
4. Patient must provide informed consent.
5. Left ventricular ejection fraction \> 40%. No uncontrolled arrhythmias or uncontrolled New York Heart Association class III-IV heart failure.
6. Bilirubin \<2mg/dl and AST and ALT \< 3 x normal; and absence of hepatic cirrhosis.
7. Adequate renal function as defined by a serum creatinine clearance of ≥ 40% of normal calculated by Cockcroft-Gault equation.
8. DLCO (diffusion capacity; corrected for hemoglobin) ≥ 50% of predicted.
9. Karnofsky performance status \> 70.
10. A negative pregnancy test will be required for all women of child bearing potential. Breast feeding is not permitted.
11. Patients with positive HIV serology are not eligible.
12. No evidence of active uncontrolled bacterial, viral or fungal infection at the time of transplant conditioning.
13. Patients with history of intolerance or allergic reactions with atorvastatin will not be eligible.
14. Patients who have previously been taking atorvastatin or any other statin drug will be eligible as long as there is no contraindication to switch to atorvastatin (40mg/day) in the opinion of the treating physician.
15. Patients undergoing a T-cell depleted allogeneic transplantation will not be eligible.
16. Patients receiving conditioning regimens containing antithymocyte globulin, and/or campath will not be eligible.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No